The role of TRPV6 in breast carcinogenesis
- PMID: 18245667
- DOI: 10.1158/1535-7163.MCT-07-0478
The role of TRPV6 in breast carcinogenesis
Erratum in
- Mol Cancer Ther. 2008 Apr;7(4):1000
Abstract
TRPV6 is an endothelial calcium entry channel that is strongly expressed in breast adenocarcinoma tissue. In this study, we further confirmed this observation by analysis of breast cancer tissues, which indicated that TRPV6 mRNA expression was up-regulated between 2-fold and 15-fold compared with the average in normal breast tissue. Whereas TRPV6 is expressed in the cancer tissue, its role as a calcium channel in breast carcinogenesis is poorly understood. Therefore, we investigated how TRPV6 affects the viability, apoptosis, and calcium transport in the breast cancer cell line T47D. Hormones can also affect the tumor development; hence, we determined the effects of estradiol, progesterone, and 1,25-vitamin D on TRPV6 transcription. Interestingly, the estrogen receptor antagonist tamoxifen reduced expression of TRPV6 and is able to inhibit its calcium transport activity (IC(50), 7.5 micromol/L). The in vitro model showed that TRPV6 can be regulated by estrogen, progesterone, tamoxifen, and 1,25-vitamin D and has a large influence on breast cancer cell proliferation. Moreover, the effect of tamoxifen on cell viability was enhanced when TRPV6 expression was silenced with small interfering RNA. TRPV6 may be a novel target for the development of calcium channel inhibitors to treat breast adenocarcinoma expressing TRPV6.
Similar articles
-
Tamoxifen inhibits TRPV6 activity via estrogen receptor-independent pathways in TRPV6-expressing MCF-7 breast cancer cells.Mol Cancer Res. 2009 Dec;7(12):2000-10. doi: 10.1158/1541-7786.MCR-09-0188. Epub 2009 Dec 8. Mol Cancer Res. 2009. PMID: 19996302
-
Calcium channel TRPV6 as a potential therapeutic target in estrogen receptor-negative breast cancer.Mol Cancer Ther. 2012 Oct;11(10):2158-68. doi: 10.1158/1535-7163.MCT-11-0965. Epub 2012 Jul 17. Mol Cancer Ther. 2012. PMID: 22807578
-
Chemical inhibitors of the calcium entry channel TRPV6.Pharm Res. 2011 Feb;28(2):322-30. doi: 10.1007/s11095-010-0249-9. Epub 2010 Nov 6. Pharm Res. 2011. PMID: 21057859
-
TRPV6.Handb Exp Pharmacol. 2007;(179):221-34. doi: 10.1007/978-3-540-34891-7_13. Handb Exp Pharmacol. 2007. PMID: 17217060 Review.
-
Human TRPV6-pathies caused by gene mutations.Biochim Biophys Acta Gen Subj. 2021 Jun;1865(6):129873. doi: 10.1016/j.bbagen.2021.129873. Epub 2021 Feb 19. Biochim Biophys Acta Gen Subj. 2021. PMID: 33610740 Review.
Cited by
-
Post-mortem histology in transient receptor potential cation channel subfamily V member 6 (TRPV6) under-mineralising skeletal dysplasia suggests postnatal skeletal recovery: a case report.BMC Med Genet. 2020 Mar 30;21(1):64. doi: 10.1186/s12881-020-01007-z. BMC Med Genet. 2020. PMID: 32228492 Free PMC article.
-
Pan-cancer analyses of clinical prognosis, immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data.Heliyon. 2023 Jun 3;9(6):e16897. doi: 10.1016/j.heliyon.2023.e16897. eCollection 2023 Jun. Heliyon. 2023. Retraction in: Heliyon. 2023 Jun 14;9(6):e17229. doi: 10.1016/j.heliyon.2023.e17229 PMID: 37346342 Free PMC article. Retracted.
-
TRPV6 modulates proliferation of human pancreatic neuroendocrine BON-1 tumour cells.Biosci Rep. 2016 Aug 24;36(4):e00372. doi: 10.1042/BSR20160106. Print 2016 Aug. Biosci Rep. 2016. PMID: 27450545 Free PMC article.
-
TRPV2 calcium channel promotes breast cancer progression potential by activating autophagy.Cancer Cell Int. 2024 Sep 27;24(1):324. doi: 10.1186/s12935-024-03506-y. Cancer Cell Int. 2024. PMID: 39334351 Free PMC article.
-
Calcium Signalling in Breast Cancer Associated Bone Pain.Int J Mol Sci. 2022 Feb 8;23(3):1902. doi: 10.3390/ijms23031902. Int J Mol Sci. 2022. PMID: 35163823 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
